摘要
目的 探讨扩张型心肌病患者采取倍他乐克的临床效果和药理作用.方法 将杭州市第一人民医院2013年1月~2017年1月收治的80例扩张型心肌病患者随机分为2组,即对照组40例和实验组40例.对照组给予常规治疗,而实验组在常规治疗的基础上给予倍他乐克治疗,观察患者的临床效果,就其治疗后的6 min步行距离(MD)、左心射血分数(LVEF)、心率(HR)、左心室舒张末期内径(LVED)以及不良反应情况进行比较.结果 经治疗,实验组患者的MD为(210.34±2.63)m、LVEF为(36.85±1.25)%、HR为(65.37±4.62)次/min、LVED为(63.27±4.57)mm,均明显优于对照组(P<0.05);实验组的不良反应情况明显少于对照组(P<0.05).结论 倍他乐克能够显著改善扩张型心肌病患者的临床指标,并且可以避免不良反应情况,有利于患者的健康.
Abstract
Objective To investigate the clinical efficacy and pharmacological effects of Betaloc in patients with dilated cardiomyopathy. Methods 80 cases of patients with dilated cardiomyopathy treated by Hangzhou First People's Hospital from January 2013 to January 2017 were selected and randomly divided control group and experimental group, 40 cases in each group. The control group was given routine treatment, while the experimental group on the basis of routine treatment were given Betaloc, observe the clinical effect on the treatment of patients. The 6min walking distance (MD), left ventricular ejection fraction (LVEF), heart rate (HR), left ventricular end diastolic diameter (LVED) were compared and the adverse reaction. Results After treatment, the patients in the experimental group of MD (210.34±2.63)m, LVEF (36.85±1.25)%, HR (65.37±4.62) times/min, LVED (63.27±4.57)mm, were better than that of the control group (P<0.05). The adverse reaction of the experimental group was significantly less than the control group, (P<0.05). Conclusion Betaloc can significantly improve the clinical parameters of patients with dilated cardiomyopathy, and can avoid adverse reactions, and is conducive to the health of patients.
NETL
NSTL
维普
万方数据